SCHEMBL12434255

SCHEMBL12434255

COCCNC(=O)c1ccccc1-c1ccccc1CNC(=O)Nc1ccc(F)cc1F

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNA5 P22460 7/20 0.54
KCNK3 O14649 1/20 0.54
KCNK5 O95279 1/20 0.54
KCNK17 Q96T54 1/20 0.54
KCNK9 Q9NPC2 1/20 0.54
MAPK1 P28482 1/20 0.51
PKM P14618 1/20 0.49
MAPT P10636 1/20 0.48
ALDH1A1 P00352 2/20 0.46
KDM4E B2RXH2 2/20 0.46
RAB9A P51151 2/20 0.45
DGAT2 Q96PD7 1/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
ATM Q13315 1/20 0.45
THRB P10828 1/20 0.43
NPC1 O15118 2/20 0.43
HPGD P15428 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
HSD17B10 Q99714 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12434279 0.90 KCNA5 (0.52) KCNA5KCNK3KCNK5KCNK17KCNK9
SCHEMBL12434257 0.83 KCNA5 (0.58) KCNA5KCNK3KCNK5KCNK17KCNK9
SCHEMBL12434245 0.82 KCNA5 (0.57) KCNA5KCNK3KCNK5KCNK17KCNK9
SCHEMBL13789552 0.82 KCNA5 (0.46) KCNA5KCNK3KCNK5KCNK17KCNK9
SCHEMBL12434266 0.82 MEN1 (0.52) KCNA5KCNK3KCNK5KCNK17KCNK9
SCHEMBL12434275 0.81 KMT2A (0.52) KCNA5KCNK3KCNK5KCNK17KCNK9
SCHEMBL12434256 0.78 KCNA5 (0.62) KCNA5MAPK1ALDH1A1RAB9ANPC1
SCHEMBL12434226 0.73 KCNA5 (0.76) KCNA5KCNK3MAPK1ALDH1A1NPC1
SCHEMBL7967927 0.72 NPC1 (0.50) MAPK1MAPTKDM4ERAB9AMEN1
SCHEMBL2208881 0.71 KCNA5 (0.70) KCNA5KCNK3KCNK5KCNK17KCNK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7982045-B2 2′-substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2011-07-19 US disclosed
US-7982045-B2 2′-substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2011-07-19 US disclosed
US-20090192096-A1 2'-Substituted 1,1'-Biphenyl-2-Carboxamides, Processes For Their Preparation, Their Use As Medicaments, And Pharmaceutical Preparations Comprising Them SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2009-07-30 US disclosed
US-20090192096-A1 2'-Substituted 1,1'-Biphenyl-2-Carboxamides, Processes For Their Preparation, Their Use As Medicaments, And Pharmaceutical Preparations Comprising Them SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2009-07-30 US disclosed
US-7514582-B2 2′-substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2009-04-07 US disclosed
US-7514582-B2 2′-substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2009-04-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090192096-A1 2'-Substituted 1,1'-Biphenyl-2-Carboxamides, Processes For Their Preparation, Their Use As Medicaments, And Pharmaceutical Preparations Comprising Them MLLT3, RYR2, CACNA1E KCNA5 90/4885KCNK3 346/4885KCNK5 472/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.